Joshua H. Bilenker, President & CEO at Loxo Oncology, Inc. (LOXO), sold 13,400 shares at $134.63 ($1.8M) on 2018-12-11, disclosed to the SEC on 2018-12-12.
Open-market sale of $1.8M LOXO by President & CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $134.63 | 647 | $87K | 4.7% |
| 2 | $135.76 | 1,153 | $157K | 8.5% |
| 3 | $136.79 | 3,393 | $464K | 25.3% |
| 4 | $136.79 | 3,393 | $464K | 25.3% |
| 5 | $137.63 | 2,407 | $331K | 18.1% |
| 6 | $137.63 | 2,407 |
| $331K |
| 18.1% |
| Total | $136.90 avg | 13,400 | $1.8M | 100% |
| Filing → |
| LOXO | SELL | 2018-12-12 | $2.7M | — | Filing → |
| LOXO | SELL | 2018-12-12 | $1.0M | — | Filing → |
| LOXO | SELL | 2018-11-28 | $1.2M | — | Filing → |